Strides Pharma Science gains 3% on USFDA approval for Lidocaine Ointment
Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the USFDA.
The share price of Strides Pharma Science gained 3.2 percent in the early trade on Thursday after it received approval for Lidocaine Ointment from the United States Food & Drug Administration (USFDA).
Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the USFDA.
Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.
The product will be marketed by Strides Pharma Inc. in the US market and will be launched immediately.
The company has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of the date and 26 are pending approval.
Strides Pharma Science was quoting at Rs 474, up Rs 10.70, or 2.31 percent on the BSE.
Are you interested in learning stock market from basic to professional trader can contact for 2 days free trial >> Stock Cash Tips
0 comments
Note: only a member of this blog may post a comment.